London.
The UK-to-US capital-bridge counterpart. FCA, Mayfair and St James's family-office cluster, non-dom reform, and the UK-to-US M&A flow.
Evaluate the city →
GMA is the global / international marketing agency treating this city as a buyer-evaluation problem inside market-entry marketing. The work is the local-market website, proof order, offer language, SEO/AI visibility, paid path, and follow-up a foreign or outbound company needs before serious buyers move.
FINMA-regulated commercial language, Lake Zurich family-office cluster, Big Four Switzerland specialist depth, and Swiss medtech, pharma, and precision-engineering adjacency. The Zurich buyer scores cross-border materials against FINMA, Swiss private-wealth conventions, named industrial reference points, and the SNB on the monetary side, not against generic European-business defaults.
Zurich runs a different commercial language from London and from Geneva. The weight sits on Swiss precision-and-private-wealth framing and on FINMA as the dominant regulator-in-residence. The FinIA and FinSA framework set the working law on the asset-management and conduct side, with the Swiss National Bank on the monetary side. The Lake Zurich family-office cluster sits in a different shape from London's Mayfair and St James's cluster. Zurich's industrial adjacency sits in a different shape from Geneva's commodities-and-private-bank surface.
Big Four Switzerland practices sit on most family-office and asset-management files. Roland Berger, Deloitte, and UBS all evaluate the Swiss private-wealth surface as a distinct register in their 2025 cross-border work. Swiss medtech, pharma, and precision-engineering names define the industrial-adjacency layer that the Zurich buyer scans for on operating files.
The diligence pass runs through FINMA-supervised counterparties, Swiss-seated trust and specialist firms, and Big Four Swiss practices. The cadence runs on longer Swiss private-wealth and institutional cycles than US pitch sequences expect, with an additional precision-and-quality judging the Zurich counterparty applies on top of the strategy.
If the Zurich counterparty asks which FINMA licence, which Swiss-seated counsel, which Big Four specialist, and which industrial reference set sit on the file, and the answer is a generic "we operate through a Zurich entity," the file is judging as not yet calibrated. The Zurich buyer is mapping the gap.
"Zurich judges the FINMA licence, the Big Four Switzerland specialist, and the industrial reference set before the strategy. The cross-border group that arrives without those signals lands as not yet in the room."House view
The first pattern is the US-RIA file arriving without FINMA literacy. The US-RIA or US institutional platform has US-side coverage, US-IR materials, and direct-broker assumptions about how the Zurich buyer will engage. The Zurich buyer scans for the FINMA licence on file, the FinIA portfolio-manager or asset-manager status, the Swiss-seated counsel, and the Big Four Switzerland specialist. The absence lands as a US-IR translation and the file is routed through the FINMA-supervised counterparty queue with reduced priority.
The second pattern is the Swiss medtech, pharma, or precision-engineering group entering the US with industrial materials still in Zurich shape. The Zurich-side website, offer, proof, and follow-up is intact. The US-side materials carry CE marks, Swiss-quality conventions, and a Swiss-engineering register that does not translate to the US procurement buyer scanning for FDA, NRTL, FCC, or other US frameworks. The Zurich-side evaluation is correct; the US-side proof requirement is the rebuild.
The third pattern is the DACH or Liechtenstein private-bank group arriving in Zurich with home-market private-bank materials. The Swiss private-wealth surface judges adjacent but not identical to the German, Austrian, or Liechtenstein register. The transplant lands as nearly-Swiss rather than Swiss-native, and the Zurich buyer scores the gap.
| Foreign supplier without rebuild | After Zurich-calibrated rebuild |
|---|---|
| Generic "Zurich-based" with no FINMA status or cluster named | FINMA status, FinIA licence type, and named cluster (Lake Zurich, Bahnhofstrasse, Zug) declared on the file |
| US-RIA deck reused for the DACH leg | FINMA-clear deck with Swiss private-wealth governance and Lake Zurich cluster framing |
| London- or Geneva-shaped materials ported across without recalibration | Zurich-side file recalibrated for FINMA, Lake Zurich cluster, and Swiss industrial adjacency |
| Big Four Switzerland specialist not named | Big Four Switzerland practice named on the materials and on the owner file |
| Industrial reference set absent on operating files | Medtech, pharma, or precision-engineering reference set named on industrial files |
| US-side materials still in Swiss-engineering register | US-side materials rebuilt for FDA, NRTL, FCC, or relevant US frameworks while Swiss-side stays native |
| Follow-up cadence on US pitch intervals | Cadence rebuilt against the longer Swiss private-wealth and FINMA cycle |
Pull the Zurich-side materials. Above the fold, is the FINMA status named, the cluster declared, the Big Four Switzerland specialist identified, and the industrial reference set scoped where the file is industrial? If no, the Zurich buyer is judging absence, and absence in this language lands as not yet calibrated.
A Market-Entry Marketing Sprint runs six to ten weeks on one narrow first question. The standard Zurich shape is a FINMA-clear deck rebuild before a family-office introduction round, a Lake Zurich owner-page rebuild calibrated against Swiss private-wealth peers, or a US-facing industrial-commercial rebuild for a Swiss medtech, pharma, or precision-engineering group whose Zurich-side register is already intact. A Cross-Border Marketing Build runs three to six months and covers the multi-channel Zurich commercial-layer rebuild for a group arriving with FINMA authorisation settled by counsel and the full Zurich-facing surface still to build.
A Global Marketing Partnership runs monthly on a twelve-month minimum and is the standard shape for groups operating multi-year Zurich presence alongside a parallel London, Dubai, Singapore, Hong Kong, or US leg. Commercial terms are set after the city file, sequence, and counterparties are known. GMA does not represent itself as a broker, intermediary, or introducer to FINMA, the SNB, any Lake Zurich family office, or any Swiss medtech, pharma, or precision-engineering counterparty. GMA rebuilds the website, offer, proof, and follow-up the client's existing or counsel-introduced work needs to land inside.
FINMA status named first. Cluster declared second. Big Four Switzerland specialist identified third. Industrial reference set scoped fourth. Cadence calibrated fifth. The Zurich-side file moves to the FINMA-clear register; US-side and other-hub files stay in their own registers.
Zurich runs the Swiss private-wealth and precision-engineering register, with FINMA as the regulator-in-residence and the SNB on the monetary side. The Lake Zurich family-office cluster sits in a different shape from London's Mayfair and St James's cluster, and Zurich's industrial and medtech-pharma adjacency sits in a different shape from Geneva's commodities-and-private-bank surface.
US private-wealth and US institutional managers covering DACH and EU, German, Austrian, and Liechtenstein private-client and institutional groups whose Zurich leg sits inside the Lake Zurich family-office cluster, Swiss medtech, pharma, and precision-engineering operating groups whose US leg is in build, and London, Singapore, and Dubai groups whose Zurich leg carries the Swiss precision and private-wealth evaluation.
No. GMA rebuilds the website, offer, proof, and follow-up that allows the client's existing or counsel-introduced Swiss family-office and Big Four specialist work to land. GMA does not broker introductions into FINMA, the Swiss National Bank, or any Zurich-seated family office.
No. FINMA authorisation including portfolio-manager and asset-manager licences, Swiss entity formation, Swiss tax structuring, and US-Switzerland double-tax treaty work are handled by the client's Swiss counsel and regulatory consultants. GMA rebuilds the website, offer, proof, and follow-up once jurisdiction and counsel are settled.
The Zurich buyer scores against FINMA literacy, Swiss private-wealth governance conventions, Lake Zurich family-office cluster fluency, Big Four Switzerland specialist adjacency, and named Swiss medtech, pharma, or precision-engineering reference points where the file is industrial. The diligence pass runs through FINMA-supervised counterparties, Swiss-seated trust and specialist firms, and the Big Four Swiss practices.
Swiss medtech and pharma names sit close to the centre of the Zurich commercial language. A cross-border group whose Zurich leg lands as a generic private-wealth entity without naming the industrial adjacency lands as having skipped a defining city signal. Where the file is industrial or operating, the medtech, pharma, or precision-engineering reference set is part of the calibration.
Inquiry through the contact form and a fit check before scope is set. Commercial terms are set after the city file, sequence, and counterparties are known.
No legal services. No Swiss or US entity formation. No FINMA authorisation applications, including FinIA portfolio-manager and asset-manager licences. No Swiss National Bank engagement. No legal jurisdiction specialist. No immigration, residence-permit, B-permit, C-permit, or related Swiss residency work. No tax structuring, transfer pricing, US-Switzerland double-tax treaty analysis, or Liechtenstein structure work. No banking introductions. No fiduciary services. No IP filing or contract drafting. No recruiting or executive search. No M&A transaction work. No introductions to FINMA, the SNB, any Lake Zurich family office, or any Swiss medtech, pharma, or precision-engineering counterparty. No brokerage of any kind. GMA rebuilds the website, offer, proof, and follow-up that allows the client's existing or counsel-introduced work to land. GMA does not represent itself as a broker, intermediary, or introducer to any Zurich-side counterparty.
These belong with the client's own Swiss and home-market counsel, tax specialist, regulatory consultant, and banker. Inquiries on these matters are returned to the client's counsel without comment.
The UK-to-US capital-bridge counterpart. FCA, Mayfair and St James's family-office cluster, non-dom reform, and the UK-to-US M&A flow.
Evaluate the city →The rule-of-law APAC counterpart. MAS, VCC, the 13O and 13U schemes, and the GIC and Temasek adjacency that defines the Singapore city buyer path.
Evaluate the city →The GCC private-client counterpart. DIFC, family offices, and the developer-adjacent buyer context that defines the Dubai buyer path.
Evaluate the city →Case-file evaluation for Swiss medtech, pharma, and precision-engineering groups rebuilding US-facing materials around US procurement evidence.
Evaluate the case file →The corridor splits into audience-specific routes. Open the route that matches the situation.
If the market is not responding, the first question is simple: what is the buyer not seeing, trusting, or doing yet?
| Action that should happen | The buyer should request a quote, ask for a call, send an RFQ, move a proposal forward, or hand the work to the right internal person. |
| What may be unclear | If that is not happening, the market may not understand the category, proof, offer, price, channel, service answer, or follow-up. |
| What to inspect | Check the page, sales deck, product proof, offer language, contact path, and follow-up before adding more traffic or more distributors. |
| Next step | If the break is commercial, continue to /engagements/ or /contact/#inquiry. |